The ability of human mesenchymal stromal/stem cells (hMSCs) to differentiate into various mesenchymal cell lineages makes them a promising cell source for the use in tissue repair strategies. Because the differentiation potential of hMSCs differs between donors, it is necessary to establish biomarkers for the identification of donors with high differentiation potential. Here, we show that microRNA (miRNA) expression levels are effective for distinguishing donors with high differentiation potential from low differentiation potential. Twenty human MSC donors were initially tested for marker expression and differentiation potential. In particular, chondrogenic differentiation potential was evaluated on the basis of histological matrix formation, mRNA expression levels of chondrogenic marker genes, and quantitative glycosaminoglycan deposition. Three donors out of twenty were identified as donors with high chondrogenic potential, whereas nine showed moderate and eight low chondrogenic potential. Expression profiles of miRNAs involved in chondrogenesis and cartilage homeostasis were used for the distinction between high-performance hMSCs and low-performance hMSCs. Global mRNA expression profiles of the donors before the onset of chondrogenic differentiation revealed minor differences in gene expression between low and high chondrogenic performers. However, analysis of miRNA expression during a seven-day differentiation period identified miR-210 and miR-630 as positive regulators of chondrogenesis. In contrast, miR-181 and miR-34a, which are negative regulators of chondrogenesis, were upregulated during differentiation in low performing donors. In conclusion, profiling of hMSC donors for a specific panel of miRNAs may have prognostic value for selecting donors with high differentiation potential to improve hMSC-based strategies for tissue regeneration.
Introduction
Human mesenchymal stromal/stem cells (hMSCs) are a multipotent cell source that can be easily harvested from various locations of the body, including bone marrow, periosteum, synovium, synovial fluid, adipose tissue, bucal fat pad, infrapatellar fat pad and osteoarthritic cartilage [1] [2] [3] [4] [5] [6] . The ability of hMSCs to differentiate into mesenchymal tissues such as bone and cartilage, and their potential as trophic mediators, renders them particularly suitable for tissue engineering [7] .
Unfortunately, large inter-donor variation of differentiation potential is a general complication for the practical implementation of hMSC-based tissue engineering approaches [8, 9] . Donor age, method or location of harvest, culture conditions as well as culture time are known to affect the differentiation potential of hMSCs [10] [11] [12] [13] [14] [15] [16] .
Jansen and colleagues suggested that distinctions in mRNA gene expression profiles might be predictive for differentiation potential [17] . However, specific biomarkers indicative for differentiation potential of undifferentiated hMSCs remain to be defined.
Studies on the genetic and epigenetic mechanisms that control the differentiation potential of hMSCs have focused on characterizing variation in both mRNA and miRNA expression levels [18] [19] [20] [21] . MicroRNAs (miRNAs) control cell fate by negatively regulating protein accumulation through effects on the stability and/or translation of mRNAs for transcription factors and their phenotypic target genes. Hence, miRNAs are very relevant molecular candidates for mapping the proliferation and differentiation potential of hMSCs.
In this study we tested a series of bone marrow derived hMSCs from a cohort of donors for their potential to undergo chondrogenesis. This cohort has previously been characterized in great detail with respect to osteogenic, adipogenic, endothelial Society for Cellular Therapy [24] . Like for differentiation into other cell types, the chondrogenic potential varied significantly between donors. The biological properties of these hMSCs were correlated with global mRNA expression profiles using microarray assays and qPCR expression analysis of a select panel of miRNAs. To permit identification of miRNAs with predictive value for chondrogenic differentiation, we examined miRNA expression both before the onset of differentiation and after the induction of chondrogenic differentiation at day seven in pellet culture. We found that miRNA profiling of hMSC donors and patients may have prognostic value in regenerative medicine by permitting identification of hMSCs that are most effective in supporting differentiation. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Materials and Methods

Cell expansion and differentiation
The use of human bone marrow aspirates was approved by local Medical Ethics Committee with written informed consent by the donors [25] . Aspirates were retrieved during total hip replacement surgery from the acetabulum or iliac crest (average age: 52 years, 25% male, 75% female). Aspirates were resuspended using a 20G needle and plated at a density of 0.5 million mononucleated cells/cm2. MSCs were selected by plastic adherence in proliferation media (α-MEM, 10% fetal bovine serum (Lonza, Verviers, Belgium), 0.2 mM ascorbic acid, 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 1 ng/mL of basic Fibroblast Growth Factor (Instruchemie, Delfzijl, The Netherlands). Human MSCs were expanded up to passage 2 and used in passage 3 to test their differentiation potential. The determination of cell surface marker expression (CD105, CD11b, CD19, CD45, HLA-DR, CD90, CD73, CD34), osteogenic potential, adipogenic potential and endothelial induction of the used hMSC donors is described elsewhere [22, 23] .
Chondrogenic differentiation
To induce chondrogenic differentiation, 250,000 hMSCs were seeded in round bottom 96 well plates [26] at passage 2. Pellets were formed by centrifugation (500 rcf, 5 min) and maintained in chondrogenic differentiation media. This medium consists of Dulbecco's modified Eagle's medium supplemented with 40 mg/mL of proline, 50 mg/mL ITS-premix, 50 mg/mL of ascorbic acid, 100 mg/mL of sodium pyruvate, 100U penicillin/mL, and 100 mg/mL streptomycin, 10 ng/mL of transforming growth This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
factor-β and 10 -7 M of dexamethasone. Cells were cultured for four weeks for determination of GAG deposition (quantitative and qualitative) and qPCR of chondrogenic markers and one week for the qPCR analysis of chondrogenesis-related miRNAs as previously described [26] . Media was changed twice a week.
Histology-Alcian Blue staining
After four weeks of chondrogenic culture pellets were fixed with 10% buffered formalin for 15 min, dehydrated and embedded in paraffin using routine procedures.
Sections of 5 µm were cut and stained for sulfated glycosaminoglycans (GAGs) with
Alcian Blue (0,5 %, in H 2 O, pH=1 adjusted with HCl, 30 min) combined with counterstaining of Nuclear Fast Red (0.1% in 5% aluminum sulfate, 5 min). Scoring of histology was performed by three independent blinded observers according to the intensity of Alcian Blue staining and morphology of the formed pellets.
mRNA isolation and quantitative polymerase chain reaction
After four weeks of chondrogenic culture total RNA was isolated from pellet cultures with the Nucleospin RNA II kit (Bioke) and 1 μg RNA was reverse-transcribed into cDNA using the iScript cDNA Synthesis kit (Bio-Rad) according to the manufacturer's protocols. The primers for quantitative polymerase chain reaction (qPCR) are listed in table 1. mRNA expression levels were normalized with GAPDH and B2M as housekeeping genes.
All reagents were purchased from Invitrogen unless otherwise stated. Common chemicals were purchased from Sigma-Aldrich. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Microarray expression profiling
Gene expression profiling of 20 hMSC donors was carried out using the Affymetrix microarray platform. RNA isolated at passage 2 before the initiation of the chondrogenic differentiation was hybridized to the Human Genome U133A 2.0 Array (Affymetrix) and scanned with a GeneChip G3000 scanner (Affymetrix).
Measurements were normalized for technical effects related to efficiency of hybridization and amplification of nucleic acids, as well as the physical location on the array. Data processing and statistical testing were performed using R and This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
chondrogenically-performing donors was generated using the approach described above.
MicroRNA isolation and quantitative polymerase chain reaction
Small RNAs were isolated from monolayer hMSC cultures at passage 2 and from pellet cultures at day seven after initiation of chondrogenic differentiation with the AllPrep DNA/RNA/Protein Mini Kit in combination with the RNeasy® MinElute®
Cleanup Kit according to the manufacturers protocol (Qiagen). Nucleic acid concentrations were measured with the Nanodrop2000. The small RNA fraction cDNA was prepared using revertAid H minus first strand cDNA synthesis kit
mRNA Primer sequences are listed in Table 2 . QuantimiR-RT kit (Systems Biosciences (SBI)) was used according to manufacturer's instruction to convert small RNAs into cDNA. Expression levels were analyzed by qRT-PCR (SYBR Green supermix and iCycler IQ detection system; Bio-Rad) using conventional protocols [30] . The relative expressions were calculated by ΔCT method normalized to U6 expression.
The qRT-PCR data were analysed using an one-way ANOVA with Tukey as post-hoc test (different sized groups) in SPSS. Significance levels of p≤0.05 are indicated with an asterisk (*). This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Results
Limited chondrogenic potential of hMSCs donors
hMSCs from a cohort of twenty donors were tested previously for their increased fibrous cartilage formation and a higher cell to matrix ratio ( Fig 1A) .
Gene expression levels of the chondrogenic genes ACAN and COL2A1 were significantly upregulated in donors with high chondrogenic potential. The chondrogenic transcription factor SOX9 and FRZB, a recently identified marker for articular cartilage, were non-significantly higher expressed in good chondrogenic performers. COL10A1, a marker for cartilage hypertrophy was significantly higher expressed in high performing donors. COL1A1, a de-differentiation marker exhibits limited variation in expression between the different groups ( Fig 1B) . Donors with high chondrogenic potential show distinct quantitative GAG levels from moderate and low performers (Fig. 1C) . Histologically assessed GAG levels did not distinguish moderate from low performing donors (Fig 1C) . Thus, high-performing chondrogenic This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
hMSCs are distinct from biologically low-performing hMSCs by both histochemical and molecular criteria.
Microarray-based mRNA expression profiling shows limited distinctions between
hMSCs with different chondrogenic potential.
Analysis of global gene expression levels between all 20 donors revealed minor mRNA expression differences between the high, moderate and low performing donors. To improve detection of molecular differences, we compared mRNA levels upon biological stratification of the donors into two groups with either high or low chondrogenic potential (n=3 in each case) using the extremes at both ends of the spectrum of chondrogenic differentiation based on histology, quantitative GAG assessment and gene expression analysis. Statistical evaluation of these highly distinct groups increased the number of significantly differentially expressed genes but differences in global gene expression levels were small (Table S1 ). STRING network analysis of genes with a minimal 1.6 fold (log ratio 0.5) upregulation in donors with high chondrogenic potential compared to low-performing donors demonstrated changes in regulatory networks associated with transcriptional control and signal transduction. One major network includes the basic helix loop-helix family member E40 (BHLHE40), which is a transcription factor modulating chondrogenesis [31] . Furthermore, several other gene regulatory factors were identified, such as nuclear receptor group 4A2 (NR4A2, also known as NURR1), as well as the basic leucine zipper (bZIP) proteins ATF3, MAFB, FOSB and FOS. Each of these regulators have been linked to signal transduction, cell proliferation and differentiation [32] (Fig 2A) . Network analysis of genes with a minimal 1.4 fold This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
downregulation in donors with low chondrogenic potential compared to donors with high chondrogenic potential revealed major networks associated with extracellular matrix proteins, such as ACAN, COL4A1, TIMP3 and EFEMP1, as well as a network of signalling proteins JAG1, dickkopf-related protein 1 (DKK1), and tumor-necrosis factor receptor superfamily member 11B (TNFRSF11B, also known as osteoprotegerin/OPG) (Fig 2B) . Ingenuity pathway analysis revealed that the ten most differentially regulated cellular functions between the three high-and the three low performing donors were linked to development, as well as cell growth and survival ( Fig 2C) . TGFβ1 was identified as a major upstream contributor to the differences in gene expression between donors with high and low chondrogenic potential ( Fig 2D) . This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. (Fig 3, Table 3 ). This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Differential expression of miRNAs between groups with distinct chondrogenic potential
Discussion
By the comparison of the chondrogenic differentiation potential of previously well characterized hMSCs from a cohort of human donors (n=20), it was shown that only 15% of these donors provide hMSCs with the natural capability to undergo efficient chondrogenic differentiation ex vivo [22, 23] , while chondrogenic performance was moderate (45%) or even poor in the remaining donors (40%). Good chondrogenic differentiation potential was mainly marked by increased GAG deposition, better histological cartilage formation including increased formation of matrix encapsulated chondrocytes (i.e., chondron formation), limited fibrous cartilage formation, as well as the significantly higher mRNA expression of ACAN and COL2A1. The main focus of our study was therefore to define molecular differences that predict high differentiation hMSC donors at the start of the differentiation experiment. We would like to emphasize that this pool of MSCs was isolated from bone marrow biopsies by virtue of plastic adherence using protocols routinely applied for isolation and culture expansion of bone marrow MSCs for clinically practice [33] . Our MSCs were not clonally selected and they are likely to present a heterogenic cell population as previously noted [24] .Previous studies have mainly focused on the osteogenic differentiation of hMSC donors.
In these studies only differences in differentiation potential were noticed and no scoring was done. Differences in performances were shown to be independent of donor age, gender, and source of isolation [9, 22, 34] . As demonstrated by our co-workers [22] high osteogenic potential of a particular donor does not imply that this donor also exhibits high chondrogenic, adipogenic or endothelial differentiation potential. We therefore want to emphasize that prognostic markers have to be identified for each differentiation linage separately.
In our study, we tested if donors with high chondrogenic potential could be identified This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
chondrogenic differentiation potential separated with a maximum 1.6-log ratio in transcript expression levels (Table S1 ). Donors with low chondrogenic potential mainly exhibited higher expression of matrix associated proteins. Donors with high chondrogenic potential showed increased expression of mRNAs involved in transcriptional processes although overall differences were small. Two regulatory networks that differ between the donor groups with high and low chondrogenic potential are centered around the basic helix loop-helix family member E40 (BHLHE40) as a transcriptional factor modulating chondrogenesis [31] and the transcription factors FOS, FOSB and ATF3, which have general roles in signal transduction, cell proliferation and differentiation [35] (Fig 2A) . This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. We find that miR-181 and miR-34a, which are negative regulators of chondrogenesis,
were upregulated during differentiation in low performing donors. Of these two, miR-34a
perturbs cartilage homeostasis by inducing apoptosis, cell cycle arrest and senescence while targeting for E2F3, cyclin E2, CDK6 and others [46, 47] , but is otherwise unremarkable.
However, similar to one of the predicted functions for miR-630, miR-181 acts as a negative regulator of the TGFβ pathway [43] . Thus, our current findings converge on a hypothetical molecular model in which miR-630 and miR-181, as well as the TGFβ/SMAD/AP-1 regulatory axis, may form a tightly connected network that modulates and predicts the chondrogenic potential of hMSCs from different donors.
In conclusion, our findings indicate that a panel of microRNAs encompassing miR-210, miR-630, miR-181 and miR-34a can be informative for prognostically separating highperforming hMSCs from low-performing hMSCs. Our data suggests that a short pre-clinical differentiation period of seven days suffices to provide insight into chondrogenic potential of different hMSCs based on miRNA expression profiling. Furthermore, modulation of TGFβ responsiveness appears to be a common mechanistic denominator in both the observed differences in mRNA expression profiles and the differences in miRNA expression between This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ fr This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Figure Legends
